Treatment of Cerebral Visual Impairment (CVI) with Invisible Infrared Technology
Cerebral Visual Impairment (CVI) encompasses a spectrum of visual deficits caused by damage to the visual pathways or centers in the brain. It can manifest in various forms, including difficulty with visual acuity, visual field defects, impaired visual processing, and challenges with visual perception. CVI is often classified into two main types: dorsal stream dysfunction, affecting spatial awareness and perception of motion, and ventral stream dysfunction, impacting object recognition and facial recognition.
Diagnosis and Classification
Diagnosing CVI involves a comprehensive assessment by an ophthalmologist or neurologist, including a detailed medical history, visual examination, and neuroimaging studies such as MRI or CT scans. Classification of CVI depends on the nature and location of the brain injury, with subtypes including cortical visual impairment (CVI), dorsal stream dysfunction, and ventral stream dysfunction. Each subtype presents distinct visual symptoms and challenges.
CVI and Neurological Eye Disorders
CVI is closely associated with neurological eye disorders, as it results from damage to the brain rather than the eyes themselves. Conditions such as optic nerve hypoplasia, cerebral palsy, traumatic brain injury, and stroke can lead to CVI. This connection underscores the importance of addressing CVI as a neurological condition that requires specialized management strategies.
Treatment with the Retyne Infrared Eye Treatment Mask
The Retyne Infrared Eye Treatment Mask offers a promising approach to alleviate symptoms of CVI. Program #4 on the Retyne controller is specifically designed to target neurological eye disorders like CVI. By utilizing invisible infrared light therapy, the Retyne mask stimulates neural pathways and promotes neuroplasticity in the visual centers of the brain. This non-invasive treatment modality holds potential for improving visual function and quality of life for individuals with CVI.
Efficacy and Benefits
Studies have shown the efficacy of infrared light therapy in enhancing visual processing and neural connectivity in individuals with CVI. The focused delivery of invisible infrared light directly to the eyes through the Retyne mask can stimulate neural regeneration and improve visual processing capabilities. Moreover, the Retynemask 's customizable programs allow for tailored treatment protocols to address the specific needs of individuals with CVI. Cerebral Visual Impairment (CVI) poses significant challenges for individuals affected by neurological eye disorders. However, with advancements in treatment modalities such as the Retyne Infrared Eye Treatment Mask, there is hope for improving visual function and quality of life. By targeting neural pathways with invisible infrared light therapy, the Retyne mask offers a promising avenue for managing the symptoms of CVI and enhancing visual outcomes.
The Retyne eye treatment mask utilizes a specific array of frequencies (0.06, 0.5, 0.87, 12.85, 27.5, 141, 301.23, 453.02, 783.4, 825.03) precisely tailored to target symptoms of Cerebral Visual Impairment (CVI). Each frequency is chosen based on documented effectiveness in managing this condition. Retyne's innovative approach converts these frequencies into invisible infrared light output, pioneering a fusion of frequencies with light. This transformative technology is a hallmark of Retyne Labs. Furthermore, the Retyne mask administers focused invisible infrared light directly onto the eyes, intensifying its therapeutic effects for CVI treatment.
Drawing inspiration from the pioneering research of Dr. Rife, who unearthed the therapeutic potential of precise frequencies and harnessed light for their propagation, Retyne's methodology embraces contemporary insights into invisible infrared technology. By leveraging current advancements and building upon historical investigations into frequency-based light transmission, Retyne has developed the innovative Retyne Eye Treatment Mask. This cutting-edge device represents the synthesis of modern breakthroughs in visual healthcare, offering a comprehensive solution rooted in both tradition and progress.
1233: Eye Infections/Inflammation [Retyne™ Lightmask ]: 0.06, 0.5, 0.87, 12.85, 27.5, 141, 301.23, 453.02, 783.4, 825.03
Cerebral visual impairment (CVI) utilizes group 1233 on the International ETDFL frequency list
Compatibility
Standalone controller (Program #4) (Controller shipped with Retyne Eye Treatment Mask)
RDPV4 (Direct connect, use group 1233)
RDPV4 Light Mask Program button 4
Click here for instructions on using the Retyne Mask + Controller
